WO2024083971 - METHOD OF DETERMINING LOSS OF HETEROZYGOSITY STATUS OF A TUMOR
National phase entry:
Publication Number
WO/2024/083971
Publication Date
25.04.2024
International Application No.
PCT/EP2023/079121
International Filing Date
19.10.2023
Title **
[English]
METHOD OF DETERMINING LOSS OF HETEROZYGOSITY STATUS OF A TUMOR
[French]
PROCÉDÉ DE DÉTERMINATION DE PERTE D'ÉTAT D'HÉTÉROZYGOSITÉ D'UNE TUMEUR
Applicants **
VIB VZW
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
LAMBRECHTS, Diether
VENKEN, Tom
BUSSCHAERT, Pieter
LOVERIX, Liselore
VAN GORP, Toon
VERGOTE, Ignace
Priority Data
22202464.8
19.10.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2216 | |
| EPO | Filing, Examination, Granting | 8965 | |
| Japan | Filing, Examination, Granting | 2124 | |
| South Korea | Filing, Examination, Granting | 2009 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,054
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
This disclosure relates to methods of determining the loss of heterozygosity (LOH) status of a tumor and to methods of determining the homologous recombination repair deficiency (HRD) status of a tumor. Such methods further translate into ways of predicting the response of a subject having cancer to treatments or therapies comprising DNA damaging agents and/or agents inhibiting or impairing DNA repair; and into use of such treatments or therapies when the LOH or HRD status of the subject having cancer is positive.[French]
La présente invention concerne des procédés de détermination de la perte d'état d'hétérozygosité (LOH) d'une tumeur et des procédés de détermination de l'état de défaut de recombinaison homologue (HRD) d'une tumeur. De tels procédés se traduisent en outre par des moyens de prédiction de la réponse d'un sujet atteint d'un cancer à des traitements ou des thérapies comprenant des agents endommageant l'ADN et/ou des agents inhibant ou affectant la réparation de l'ADN ; et par l'utilisation de tels traitements ou thérapies lorsque l'état LOH ou HRD du sujet atteint d'un cancer est positif.